Fallopian Tube Cancer
📧 Sign up to get email alerts when something new happens for Fallopian Tube Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-05-09Clinical Trial Update: LCC-CARIS-01: Molecular Profiling in Gynaecological Cancer [NA]
The LCC-CARIS-01 trial focusing on molecular profiling in gynecologic cancers has completed. The study included epithelial ovarian cancer, p…
-
CLINICAL_TRIALS trial_result · 2024-05-07Clinical Trial Update: CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib [Phase 3]
Phase 3 rollover study CATCH-R provides continued access to rucaparib for eligible patients with metastatic castration-resistant prostate ca…
-
CLINICAL_TRIALS trial_result · 2024-04-26Clinical Trial Update: Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer [Phase 1]
The Phase 1 study of KHK2866, an HB-EGF–targeting antibody, in advanced solid tumors and ovarian cancer has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-04-18Clinical Trial Update: A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors [Phase 1, Phase 2]
Phase 1/2 trial of DSP-7888 Dosing Emulsion in combination with immune checkpoint inhibitors in adults with advanced solid tumors was termin…
-
CLINICAL_TRIALS trial_result · 2024-04-15Clinical Trial Update: Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer [Phase 2]
Phase 2 clinical trial evaluating pembrolizumab in participants with recurrent ovarian, fallopian tube, or primary peritoneal carcinoma.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-02-14Clinical Trial Update: Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer [Phase 1, Phase 2]
A Phase 1/2 trial evaluating mirvetuximab soravtansine in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin, or pem…
-
CLINICAL_TRIALS trial_result · 2024-01-17Clinical Trial Update: Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor [Phase 2]
Phase 2 clinical trial evaluating a genetic profile–guided treatment strategy for ovarian cancer patients who previously received a PARP inh…
-
CLINICAL_TRIALS trial_result · 2024-01-17Clinical Trial Update: A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer [Phase 2]
Phase 2 trial evaluating olaparib given before surgery and chemotherapy in ovarian, primary peritoneal, and fallopian tube cancers; current …
-
CLINICAL_TRIALS trial_result · 2024-01-10Clinical Trial Update: Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer [Phase 1, Phase 2]
Phase 1/2 trial evaluating avelumab with or without entinostat in advanced epithelial ovarian cancer and peritoneal cancer has completed; re…
-
CLINICAL_TRIALS trial_result · 2023-12-11Clinical Trial Update: Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating pazopanib hydrochloride with paclitaxel and carboplatin in patients with refractory or resistant ovari…
-
CLINICAL_TRIALS trial_result · 2023-12-07Clinical Trial Update: Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi [Phase 2]
Phase 2 trial evaluating fluzoparib with or without apatinib in platinum-sensitive relapsed ovarian cancer previously treated with PARP inhi…
-
CLINICAL_TRIALS trial_result · 2023-11-07Clinical Trial Update: Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC). [Phase 2]
Phase 2 trial of pembrolizumab with paclitaxel and carboplatin in advanced epithelial ovarian cancer (and fallopian tube/peritoneal cancers)…
-
CLINICAL_TRIALS trial_result · 2023-10-26Clinical Trial Update: Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) [Phase 3]
A Phase 3 trial of Upifitamab Rilsodotin (Upifitamab Rilsodotin) in maintenance therapy for platinum-sensitive recurrent ovarian cancer has …
-
CLINICAL_TRIALS trial_result · 2023-10-13Clinical Trial Update: Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer [Phase 2]
Phase 2 trial evaluating the addition of tremelimumab to olaparib for recurrent ovarian, fallopian tube, or primary peritoneal cancer; the s…
-
CLINICAL_TRIALS trial_result · 2023-10-12Clinical Trial Update: BrUOG 390: Neoadjuvant Treatment With Talazoparib [Phase 1]
Phase 1 neoadjuvant study of talazoparib in BRCA1/BRCA2 mutation-associated cancers ( ovarian/fallopian tube high-grade serous carcinoma) ha…
-
CLINICAL_TRIALS trial_result · 2023-10-04Clinical Trial Update: TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors [Phase 1]
Phase 1 results for a study combining the TORC1/2 inhibitor MLN0128 (sapanisertib) with bevacizumab in adults with recurrent glioblastoma or…
-
CLINICAL_TRIALS trial_result · 2023-09-15Clinical Trial Update: Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial [Phase 2, Phase 3]
Trial update for intraperitoneal therapy with carboplatin in epithelial ovarian cancer and related conditions; the study has completed phase…
-
CLINICAL_TRIALS trial_result · 2023-09-15Clinical Trial Update: Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009) [Phase 1]
Phase 1 trial evaluating autologous T cells with or without cyclophosphamide and fludarabine for recurrent or persistent advanced ovarian ep…
-
CLINICAL_TRIALS trial_result · 2023-09-08Clinical Trial Update: Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 2]
Phase 2 clinical trial update evaluating gemcitabine hydrochloride with or without the WEE1 inhibitor adavosertib in patients with recurrent…
-
CLINICAL_TRIALS trial_result · 2023-08-07Clinical Trial Update: BEACON - ABC in Recurrent Platinum Resistant HGSOC [Phase 2]
Phase 2 trial update for BEACON program in recurrent platinum-resistant high-grade serous ovarian cancer (HGSOC).
-
CLINICAL_TRIALS trial_result · 2023-07-19Clinical Trial Update: Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer [Phase 1, Phase 2]
Clinical trial update of veliparib combined with topotecan hydrochloride in adults with solid tumors, relapsed or refractory ovarian cancer,…
-
CLINICAL_TRIALS trial_result · 2023-06-26Clinical Trial Update: High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy [Phase 3]
A Phase 3 trial evaluating high-dose inorganic selenium for preventing chemotherapy-induced peripheral neuropathy in ovarian cancer patients…
-
CLINICAL_TRIALS trial_result · 2023-05-24Clinical Trial Update: Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment [Phase 2]
A Phase 2 clinical trial investigating oregovomab and pegylated liposomal doxorubicin (PLD) in patients with PARP inhibitor–resistant ovaria…
-
CLINICAL_TRIALS trial_result · 2023-05-06Clinical Trial Update: A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) [Phase 2]
Phase 2 safety-run-in update for weekly tisotumab vedotin in platinum-resistant ovarian cancer (innovaTV 208) completed, with results posted…
-
CLINICAL_TRIALS trial_result · 2023-05-06Clinical Trial Update: IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer [Phase 2]
Phase 2 trial evaluating ALT-803 administered subcutaneously after initial ALT-803 treatment for ovarian cancer, fallopian tube cancer, and …